EU nod for Astellas's Modigraf for transplant rejection
This article was originally published in Scrip
The EU's CHMP has adopted a positive opinion on Astellas' oral suspension formulation of its immunosuppressive drug tacrolimus (Modigraf) for the prophylaxis of transplant rejection in kidney, liver or heart allograft recipients, and treatment of allograft rejection resistant to treatment with other immunosuppressive products in adult and paediatric patients.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.